155
Participants
Start Date
December 31, 2008
Primary Completion Date
July 31, 2009
Study Completion Date
August 31, 2010
LX1031 High Dose
A high dose of LX1031; daily oral intake for 28 days
LX1031 Low Dose
A low dose of LX1031; daily oral intake for 28 days.
Placebo
Matching placebo dosing with daily oral intake
Long Island Clinical Research, Great Neck
National Clinical Research Norfolk Inc., Norfolk
Piedmont Medical Associates, Winston-Salem
Medoff Medical/Vital re:Search, Greensboro
Cary Medical Research, Cary
The UNC Center for Functional GI & Motility Disorders, Chapel Hill
Unifour Medical Research, Hickory
Coastal Carolina Research Center in Goose Creek, Goose Creek
Clinical Research Atlanta, Stockbridge
Accord Clinical Research, LLC, Port Orange
Research Consultants Group, Hialeah
Consultants for Clinical Research of S. Florida, Boynton Beach
Clinical Trials Management of Boca Raton, Inc., Boca Raton
ClinSearch, Chattanooga
Consultants for Clinical Research, Cincinnati
Gastroenterology Research Consultant of Greater Cincinnati, Cincinnati
Aurora Health Center - Waukesha, Waukesha
Mayo Clinic, Rochester
Arkansas Gastroenterology, Sherwood
Oklahoma Foundation for Digestive Research, Oklahoma City
Lynn Health Science Institute, Oklahoma City
Pioneer Research Solutions, Houston
Houston Medical Research Associates, Houston
Lynn Instiute of the Rockies, Colorado Springs
Northwest Clinical Trials, Boise
Utah Clinical Trials, LLC, Salt Lake City
Advanced Research Institute, Ogden
Genova Clinical Research, Tucson
Affiliated Clinical Research, Las Vegas
Impact Clinical Trials, Los Angeles
Medical Associates Research Group, San Diego
Edinger Medical Group Clinical Research Center, Fountain Valley
Advanced Clinical Research Institute, Anaheim
Community Clinical Trials, Orange
AGMG - Orange, Orange
ActivMed Practice and Research, Haverhill
Lead Sponsor
Lexicon Pharmaceuticals
INDUSTRY